The differential risk of oral contraceptives: the impact of full exposure history*
Authors:
- K D MacRaeKMK D MacRae
- D Kühl-HabichlDKD Kühl-Habichl
- R BruppacherRBR Bruppacher
- L A HeinemannLHL A Heinemann
- W O SpitzerWSW O Spitzer
- 1 June 1999
- journal article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 14 (6) , 1493-1499
Abstract
Previous discussions have indicated that the small increases of risk of venous thromboembolism (VTE) associated with newer combined oral contraceptives (third generation, containing desogestrel and gestodene) may be attributed to bias due to cohort effects. In a case-control analysis, this may produce an overestimate of risk of newer preparations. In 10 centres in Germany and the UK, the Transnational Study analysed data from 502 women aged 16-44 years with VTE, and from 1864 controls matched for 5-year age group and region. Information on lifetime exposure history from all subjects was added to the dataset used in previous analyses and entered into a Cox regression model with time-dependent covariates. Based on 17 622 continuous exposure episodes comprising 47 914 person-years of observation, the adjusted hazard ratio (equivalent to odds ratio, OR) of VTE for the comparison of current users of third-generation versus current users of second-generation (primarily levonorgestrel compounds) combined oral contraceptives was 0.8 (0.5 to 1.3). The OR obtained in standard case-control analysis had been 1.5 (1.1 to 2.1). Adjustment for past exposures includes more information and appears more valid than the standard cross-sectional analysis. Using this approach, the Transnational Study data show no evidence for an increased risk of VTE with third- compared with second-generation combined oral contraceptives.Keywords
This publication has 22 references indexed in Scilit:
- Case-control study of oral contraceptives and risk of thromboembolic stroke: results from international study on oral contraceptives and health of young womenBMJ, 1997
- Oral contraceptives and venous thromboembolismThe Lancet, 1997
- Population-based study of risk of venous thromboembolism associated with various oral contraceptivesThe Lancet, 1997
- The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational researchContraception, 1996
- Interim review of the transnational case-control study of oral contraceptives and health: approved protocol revisions through September 1995Pharmacoepidemiology and Drug Safety, 1996
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagenThe Lancet, 1995
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- Modelling Survival Data in Medical Research1994
- Relation of pooled logistic regression to time dependent cox regression analysis: The framingham heart studyStatistics in Medicine, 1990